# Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects

> **NCT03901781** · PHASE1 · COMPLETED · sponsor: **Noveome Biotherapeutics, formerly Stemnion** · enrollment: 9 (actual)

## Conditions studied

- Ocular Hypertension

## Interventions

- **COMBINATION_PRODUCT:** ST266 via Intranasal Delivery

## Key facts

- **NCT ID:** NCT03901781
- **Lead sponsor:** Noveome Biotherapeutics, formerly Stemnion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-23
- **Primary completion:** 2022-05-20
- **Final completion:** 2022-05-20
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03901781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03901781, "Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03901781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*